No Data
RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target
RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price target.
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $32
RBC Capital analyst Leonid Timashev maintains $Edgewise Therapeutics(EWTX.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 48
Edgewise Therapeutics (EWTX) Receives a Buy From RBC Capital
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) adding 0.4%.The iShares Biotechnology ETF (
Express News | Edgewise Therapeutics Shares Are Trading Higher After JP Morgan Maintained an Overweight Rating and Raised the Price Target From $27 to $30
Top Midday Gainers
Edgewise Therapeutics (EWTX) climbed 8.2% after analysts at JPMorgan increased its price target for the biopharmaceuticals company to $30 from $27 a share previously.Volume stood at more than 668,300
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long